CMN Weekly (1 August 2025) - Your Weekly CRISPR...
CMN Weekly
Aug. 1, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
RheumaGen
Company type: Therapeutics
Main focus: Engineered haematopoietic stem cells (HSCs)
Company stage: Pre-clinical
Diseases: Rheumatoid arthritis, ankylosing spondylitis, multiple sclerosis, type 1 diabetes, and coeliac disease
Genome-editing tool: CRISPR
Funding stage: Seeding
Location: Denver, CO
Website: https://www.rheumagen.com
Pipeline: https://www.rheumagen.com/our-science
Partners:
RheumaGen is a pre-clinical-stage company focused on eradicating autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, multiple sclerosis, type 1 diabetes, and coeliac disease. This is achieved via ex vivo CRISPR editing of patient-derived haematopoietic stem cells to remove the human leukocyte antigen (HLA) marker, which triggers the auto-reaction by a patient's immune system. Currently, RG0401 is being investigated in pre-clinical studies for the treatment of refractory rheumatoid arthritis.
